Palavras-chave
Obesidade
Fatores de Risco
Comorbidades
Consequências
Como Citar
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Resumo
Objetivo: Relacionar as consequências da COVID-19 com os achados das pesquisas realizadas em pacientes com obesidade que foram atingidos pela doença. Revisão bibliográfica: A literatura internacional sugere uma relação significativa entre a obesidade e a gravidade da COVID-19. A realização de investigações utilizando protocolos clínicos e epidemiológicos é crucial para estabelecer de forma mais precisa a conexão entre a obesidade e o risco de complicações da COVID-19. Essas pesquisas podem ajudar a obter uma compreensão mais aprofundada dessa associação e identificar os fatores subjacentes que contribuem para as complicações concomitantes em pacientes com sobrepeso. Considerações finais: A obesidade é uma doença crônica não transmissível, representando um fator de risco significativo para o agravamento da COVID-19. No entanto, é essencial ressaltar que ela é passível de prevenção. A adoção de hábitos saudáveis de vida não apenas pode mitigar os riscos associados à obesidade, mas também tem o potencial de reduzir a gravidade das infecções pela COVID-19, considerando que ambas são condições caracterizadas por processos inflamatórios.
Referências
AMARAL LMB, et al. Vias metabólicas e hiperinflamação na COVID 19 em obesos diabéticos renais crônicos e sua reabilitação física pós-infecção / Metabolic pathways and hyperinflammation in COVID 19 in obese and chronic renal diabetic patients and their post-infection physical rehabilitation. Brazilian Journal of Development, 2021; 7: 67591-67615.
APOVIAN CM, et al. Body Weight Considerations in the Management of Type 2 Diabetes. Advances in therapy, 2019; 36(1): 44-58.
ATKINSON RL, et al. Human adenovirus-36 is associated with increased body weight and paradoxical reduction of serum lipids. Int J Obes, 2005; 29(9): 281-286.
BARROSO WA, et al. Metabolic syndrome and COVID-19: An update on the associated comorbidities and proposed therapies. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2020; 14: 809-814.
BEZERRA et al. Factors associated with people’s behavior in social isolation during the covid-19 pandemic. Ciência e Saúde Coletiva, 2020; 25: 2411-2421.
BRANDÃO S, et al. Obesidade e risco de COVID-19: grave [livro eletrônico]. Recife, 2020; 1.
BURGOS-MORÓN E, et al. Relationship Between Oxidative Stress, ER Stress, and Inflammation in Type 2 Diabetes: The Battle Continues. J Clin Med, 2019; 9: 1385.
CAMPOS MR, et al. Carga de doença da COVID-19 e de suas complicações agudas e crônicas: reflexões sobre a mensuração (DALY) e perspectivas no Sistema Único de Saúde. Cadernos de Saúde Pública [online], 2020; 36: 11.
CARNETHON M. The Biggest Health Problem: Obesity. Sci Am, 2019; 1.
DANTZER, et al. Resilience and immunity. Brain BehavImmun, 2018; 74: 28-42.
DIETZ WSC. Obesity and its implications for COVID-19 mortality. Obesity (Silver Spring), 2020; 28(6): 1005.
DURÃES SA, et al. Implicações da pandemia da covid-19 nos hábitos alimentares. Revista Unimontes Científica, 2020; 22: 1-20.
GABBRIELLI R e PUGNO NM. The impact of mean body mass index on reported mortality from COVID-19 across 181 countries. Frontiers in public health, 2023; 11: 1106313.
GALLEGO P, et al. Adults with congenital heart disease during the coronavirus disease 2019 (COVID-19) pandemic: are they at risk? Revista, 2020; 73(10): 795-798.
GUO W, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev, 2020; 31: 3319.
HONCE RSS. Impact of obesity on influenza a virus pathogenesis, immune response, and evolution. Front Immunol, 2019; 10: 1071.
KALLIGEROS M, et al. Association of obesity with disease severity among patients with coronavirus disease 2019. Obesity (Silver Spring), 2020; 28(7): 1200-4.
KIRWAN R, et al. Sarcopenia During Covid-19 Lockdown Restritions: Long-Term Health Effects of Short-Term Muscle Loss. Geroscience, 2020; 42(6): 1547-1578.
KRAUSE M, et al. Coronavirus infection (SARS-CoV-2) in obesity and diabetes comorbidities: is heat shock response determinant for the disease complications? Diabetol Metab Syndr, 2020; 16: 12-63.
LIM S, et al. Proper Management of People With Obesity During the COVID-19 Pandemic. J. Obes. Metab. Syndr, 2020; 29(2): 84-98.
LUZI L e RADAELLE MG. Influenza and obesity: its odd relationship and the lessonsfor COVID-19 pandemic. Acta Diabetol, 2020; 57(6): 759-764.
MCMICHAEL TM, et al. Public Health–Seattle and King County, EvergreenHealth, and CDC COVID-19 Investigation Team. Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington. N Engl J Med, 2020; 382(21): 11.
MICHALAKIS K e ILIAS I. SARS-CoV-2 infection and obesity: common inflammatory and metabolic aspects. Diabetes Metab Syndr, 2020; 14(4): 69-71.
NASI, et al. The role of physical activity in individuals with cardiovascular risk factors: an opinion paper from Italian Society of Cardiology-Emilia Romagna-Marche and SIC-Sport. J Cardiovasc, 2019; 20(10): 631-639.
OLIVEIRA ML, et al. Direct healthcare cost of obesity in Brazil: An application of the cost-of-illness method from the perspective of the public health system in 2011. PLoS One, 2015; 10: 4.
OLIVEROS, et al. The concept of normal weight obesity. Prog Cardiovasc Dis, 2014; 56(4): 426-433.
OXLEY TJ, et al. Large-vessel stroke as apresenting feature of Covid-19 in the young. NEngl J Med, 2020; 382: 60.
PECANHA, et al. Social isolation during the COVID-19 pandemic can increase physical inactivity and the global burden of cardiovascular disease. Am J Physiol Circ Physiol, 2020; 318(6): 1441-1446.
RYAN PM e CAPLICE NM. Is adipose tissue a reservoir for viral spread, immune activation, and cytokine amplification in coronavirus disease 2019? Obesity (Silver Spring), 2020; 28(7): 1191-1194.
SALES-PERES SHC, et al. Coronavirus (SARS-CoV-2) and the risk of obesity for critically illness and ICU admitted: Meta-analysis of the epidemiological evidence. Obes Res Clin Pract [online], 2020; 14: 389-397.
SBCBM Sociedade Brasileira de Cirurgia Bariátrica e Metabólica. Obesidade atinge mais de 6,7 milhões de pessoas no Brasil em 2022. SISVAN, 2023; 1-3.
SILVA GM, et al. Obesidade como fator agravante da COVID-19 em adultos hospitalizados: revisão integrativa. Acta Paulista de Enfermagem, 2021; 34.
SONZA, et al. Brazil before and during covid-19 pandemic: Impact on the practice and habits of physical exercise. Acta Biomed, 2021; 92(1):1-10.
STEFAN N, et al. Global pandemics interconnected – obesity, impaired metabolic health and COVID-19. Nat Rev Endocrinol, 2021; 1.
TANG, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost, 2020; 18(4): 844-847.
WORLD HEALTH ORGANIZATION (WHO). Coronavirus disease (COVID-19) Situation Report Region. Data as received by WHO from national authorities by 10:00 CEST, 15 set 2023. Geneva: WHO; 2023; 1.
WU D, et al. Plasma metabolomic and lipidomic alterations associated with COVID-19. Med Rxiv, 2020; 26.
ZHANG C, et al. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol, 2020; 5: 428-30.